JP2025521083A - ＨＰＫ１阻害剤としてのテトラヒドロピリド［３，４－ｄ］ピリミジン化合物 - Google Patents

ＨＰＫ１阻害剤としてのテトラヒドロピリド［３，４－ｄ］ピリミジン化合物 Download PDF

Info

Publication number
JP2025521083A
JP2025521083A JP2024566233A JP2024566233A JP2025521083A JP 2025521083 A JP2025521083 A JP 2025521083A JP 2024566233 A JP2024566233 A JP 2024566233A JP 2024566233 A JP2024566233 A JP 2024566233A JP 2025521083 A JP2025521083 A JP 2025521083A
Authority
JP
Japan
Prior art keywords
mmol
group
pyrido
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025521083A5 (enExample
Inventor
トゥーレ モマー
リー ピン
ニーグ コンスタンティン
ワン イェンピン
ジョンソン テレサ
ウンズエ ロペス アンドレア
シャオ ユーファン
フリース エミリー
ディポト マリア
ギュラー サテニグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2025521083A publication Critical patent/JP2025521083A/ja
Publication of JP2025521083A5 publication Critical patent/JP2025521083A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024566233A 2022-05-10 2023-05-04 ＨＰＫ１阻害剤としてのテトラヒドロピリド［３，４－ｄ］ピリミジン化合物 Pending JP2025521083A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263340191P 2022-05-10 2022-05-10
US63/340,191 2022-05-10
US202263383190P 2022-11-10 2022-11-10
US63/383,190 2022-11-10
PCT/US2023/066601 WO2023220541A1 (en) 2022-05-10 2023-05-04 Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors

Publications (2)

Publication Number Publication Date
JP2025521083A true JP2025521083A (ja) 2025-07-08
JP2025521083A5 JP2025521083A5 (enExample) 2026-05-14

Family

ID=86688794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566233A Pending JP2025521083A (ja) 2022-05-10 2023-05-04 ＨＰＫ１阻害剤としてのテトラヒドロピリド［３，４－ｄ］ピリミジン化合物

Country Status (9)

Country Link
US (1) US20240025922A1 (enExample)
EP (1) EP4522618A1 (enExample)
JP (1) JP2025521083A (enExample)
CN (1) CN119546610A (enExample)
AU (1) AU2023267747A1 (enExample)
CA (1) CA3250387A1 (enExample)
IL (1) IL316818A (enExample)
TW (1) TW202400612A (enExample)
WO (1) WO2023220541A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025210407A1 (en) * 2024-04-01 2025-10-09 Merck Patent Gmbh (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019010302A (es) * 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.

Also Published As

Publication number Publication date
TW202400612A (zh) 2024-01-01
CA3250387A1 (en) 2023-11-16
AU2023267747A1 (en) 2024-11-07
IL316818A (en) 2025-01-01
WO2023220541A1 (en) 2023-11-16
CN119546610A (zh) 2025-02-28
US20240025922A1 (en) 2024-01-25
EP4522618A1 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
AU2019216728B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
RU2617405C2 (ru) Пиридоновые и азапиридоновые соединения и способы применения
CN111867590B (zh) Atr激酶的杂环抑制剂
EP4010335A1 (en) Shp2 inhibitors
US20210393623A1 (en) Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
EP3601259A1 (en) Isoquinolines as inhibitors of hpk1
CA2897333A1 (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
JP2022502424A (ja) モノアシルグリセロールリパーゼ調節因子
US20220306640A1 (en) Hydantoin derivative
US20240109900A1 (en) Azabicyclic shp2 inhibitors
JP2023534837A (ja) アンドロゲン受容体モジュレーターとしてのインドール化合物
WO2022207924A1 (en) (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
KR20210100612A (ko) 시클로알칸-1,3-디아민 유도체
AU2019363657B2 (en) 5-azaindazole derivatives as adenosine receptor antagonists
KR20210083287A (ko) 아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
AU2023267747A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
BR112014010459B1 (pt) Compostos e composição farmacêutica
BR122020017743B1 (pt) Processo para fabricação de uma composição farmacêutica e uso de uma composição farmacêutica
NZ624021B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260501